CRISPR Therapeutics AG (CRSP) Accumulated Depreciation (2015 - 2026)

CRISPR Therapeutics AG has disclosed Accumulated Depreciation across 12 years of filings, most recently posting $99.6 million for Q2 2026.

• In Q2 2026, Accumulated Depreciation rose 22.05% year-over-year to $99.6 million; the TTM figure through Jun 2026 stood at $99.6 million (up 22.05% YoY), while the FY2025 annual figure was $91.1 million, up 25.99% from the prior year.
• Accumulated Depreciation came in at $99.6 million for Q2 2026 at CRISPR Therapeutics AG, up from $95.3 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $99.6 million in Q2 2026 to a low of $28.0 million in Q3 2022.
• Average Accumulated Depreciation over 5 years is $62.9 million, with a median of $60.7 million recorded in 2024.
• The largest YoY upside for Accumulated Depreciation was 85.67% in 2022 against a maximum downside of 14.8% in 2022.
• Over 5 years, Accumulated Depreciation stood at $33.8 million in 2022, then jumped by 57.94% to $53.4 million in 2023, then soared by 35.26% to $72.3 million in 2024, then gained by 25.99% to $91.1 million in 2025, then gained by 9.38% to $99.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $99.6 million in Q2 2026, $95.3 million in Q1 2026, and $91.1 million in Q4 2025.